Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

PRLD holding history

Prelude Therapeutics Inc in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

PRLD overviewAll 13F holders of PRLDFull Q2 2026 holdings

Shares (Q2 2026)
318,797
Value
$1.70M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of PRLD by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026318,797$1.70M<0.1%+254,292+394.2%AddedHolders
Q1 202664,505$220.6K<0.1%+62,648+3,373.6%AddedHolders
Q4 20251,857$5.38K<0.1%−2,314−55.5%ReducedHolders
Q3 20254,171$6.01K<0.1%−100,033−96.0%ReducedHolders
Q2 2025104,204$84.3K<0.1%+8,048+8.4%AddedHolders
Q1 202596,156$73.8K<0.1%+28,766+42.7%AddedHolders
Q4 202467,390$85.9K<0.1%+60,374+860.5%AddedHolders
Q3 20247,016$14.5K<0.1%−3,918−35.8%ReducedHolders
Q2 202410,934$41.7K<0.1%−4,721−30.2%ReducedHolders
Q1 202415,655$74.2K<0.1%−4,218−21.2%ReducedHolders
Q4 202319,873$84.9K<0.1%+12,465+168.3%AddedHolders
Q3 20237,408$22.9K<0.1%+516+7.5%AddedHolders
Q2 20236,892$31.0K<0.1%+5,912+603.3%AddedHolders
Q1 2023980$5.59K<0.1%−57−5.5%ReducedHolders
Q4 20221,037$6.26K<0.1%+969+1,425.0%AddedHolders
Q3 202268$00.0%−2,638−97.5%ReducedHolders
Q2 20222,706$14.0K<0.1%+2,523+1,378.7%AddedHolders
Q1 2022183$1.00K<0.1%−1,755−90.6%ReducedHolders
Q4 20211,938$23.0K<0.1%−35,063−94.8%ReducedHolders
Q3 202137,001$1.16M<0.1%+29,433+388.9%AddedHolders
Q2 20217,568$216.0K<0.1%−14,768−66.1%ReducedHolders
Q1 202122,336$968.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.